Results 51 to 60 of about 203,532 (254)

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

open access: yesMolecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera   +11 more
wiley   +1 more source

Application of Artificial Neural Network in Predicting the Survival Rate of Gastric Cancer Patients [PDF]

open access: yesIranian Journal of Public Health, 2011
"nBackground: The aim of this study was to predict the survival rate of Iranian gastric cancer patients using the Cox proportional hazard and artificial neural network models as well as comparing the ability of these approaches in predicting the ...
A Biglarian   +3 more
doaj   +2 more sources

Modelling non-life insurance in Sri Lanka using Cox Hazard Model and classification of risky customers

open access: yesRuhuna Journal of Science, 2020
Some of the major factors that help the decision-making process of an insurance company include Time of the first claim (TFC), claim Size and the frequency of claims.
W.A.R. De Mel , W.A.P.A. Chathurangani
doaj   +1 more source

Standard errors for the cox proportional hazards cure model

open access: yesMathematical and Computer Modelling, 2001
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Sy, J. P., Taylor, J. M. G.
openaire   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

COX PROPORTIONAL HAZARD AND EXPONENTIAL SURVIVAL ANALYSIS IN PATIENTS WITH END-STAGE CHRONIC KIDNEY FAILURE AT BOJONEGORO

open access: yesBarekeng
End-stage chronic renal failure is a condition that requires long-term treatment such as haemodialysis and poses a serious threat to patient survival.
Nur Silviyah Rahmi   +3 more
doaj   +1 more source

Deep learning approach for survival prediction for patients with synovial sarcoma

open access: yesTumor Biology, 2018
Synovial sarcoma is a rare disease with diverse progression characteristics. We developed a novel deep-learning-based prediction algorithm for survival rates of synovial sarcoma patients.
Ilkyu Han   +4 more
doaj   +1 more source

The trend of change in cervical tumor size and time to death of hospitalized patients in northwestern Ethiopia during 2018–2022: Retrospective study design

open access: yesHealth Science Reports, 2023
Background and Aims Cervical cancer is the fourth most common cause of cancer‐related death in the world. The objective of this study was to determine factors that affect the longitudinal change of tumor size and the time to death of outpat Methods A ...
Aragaw E. Aguade   +2 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy